Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CBIO
stocks logo

CBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 25.25 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 25.25 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.990
sliders
Low
22.00
Averages
25.25
High
28.00
Current: 12.990
sliders
Low
22.00
Averages
25.25
High
28.00
Jefferies
NULL
to
Buy
initiated
$26
2025-08-25
Reason
Jefferies
Price Target
$26
2025-08-25
initiated
NULL
to
Buy
Reason
Jefferies initiated coverage of Crescent Biopharma with a Buy rating and $26 price target. Crescent is a preclinical-stage oncology company with CR-001 as its lead asset, the analyst tells investors in a research note. Jefferies believes in the PD-(L)1xVEGF class and sees an "intriguing" risk/reward at current share levels.
H.C. Wainwright
NULL -> Buy
initiated
$25
2025-08-11
Reason
H.C. Wainwright
Price Target
$25
2025-08-11
initiated
NULL -> Buy
Reason
H.C. Wainwright initiated coverage of Crescent Biopharma with a Buy rating and $25 price target. The company's lead asset, CR-001, is a bispecific antibody targeting programmed cell death protein 1 and vascular endothelial growth factor, the analyst tells investors in a research note. The firm sees an attractive valuation at current share levels and views Crescent as a potential takeover target.
Wedbush
Outperform
initiated
$27
2025-07-14
Reason
Wedbush
Price Target
$27
2025-07-14
initiated
Outperform
Reason
Wedbush initiated coverage of Crescent Biopharma with an Outperform rating and $27 price target. The firm says Crescent is an oncology-focused company developing programs for the treatment of solid tumors. Wedbush expects the company's additional topoisomerase-1 inhibitor-based antibody drug conjugate programs CR-002 and CR-003 to allow for synergistic combinations with CR-001 and drive "differentiated activity with validated mechanisms."
Stifel
Buy
initiated
$28
2025-06-24
Reason
Stifel
Price Target
$28
2025-06-24
initiated
Buy
Reason
TD Cowen
TD Cowen
Buy
initiated
2025-06-21
Reason
TD Cowen
TD Cowen
Price Target
2025-06-21
initiated
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Crescent Biopharma Inc (CBIO.O) is -1.61, compared to its 5-year average forward P/E of -1.92. For a more detailed relative valuation and DCF analysis to assess Crescent Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.92
Current PE
-1.61
Overvalued PE
-0.30
Undervalued PE
-3.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CBIO News & Events

Events Timeline

(ET)
2025-11-06
07:35:13
Crescent Biopharma Announces Q3 Earnings Per Share of $1.27, Below Estimates of $1.38
select
2025-11-04 (ET)
2025-11-04
09:10:26
Crescent Biopharma to Showcase Preclinical Findings for CR-001
select
2025-07-31 (ET)
2025-07-31
07:36:49
Crescent Biopharma sees cash runway through 2027
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
00:29 AMBenzinga
What’s Going On With Crescent Biopharma Stock Today?

  • Partnership Announcement: Crescent Biopharma has formed an exclusive partnership with Sichuan Kelun-Biotech to develop next-generation oncology therapeutics, including the bispecific antibody CR-001 and various antibody-drug conjugates.

  • Private Placement Details: The company secured a $185 million private placement to support clinical development, with expected closure around December 8, 2023, and participation from several investment firms.

  • Pipeline Timeline: Crescent anticipates that its products CR-001, CR-002, and CR-003 will enter clinical trials in 2026, with initial proof-of-concept data expected in 2027.

  • Market Reaction: Following the announcement, Crescent Biopharma's shares experienced a decline of 2.31%, trading at $13.10 at the time of reporting.

[object Object]
Preview
7.5
12-04NASDAQ.COM
Crescent and Kelun-Biotech Finalize Oncology Partnership; Crescent Plans to Raise $185 Million; Stock Price Increases

  • Partnership Announcement: Crescent Biopharma, Inc. has formed an exclusive partnership with Sichuan Kelun-Biotech to develop and commercialize oncology therapeutics, including CR-001 and SKB105, with both expected to enter Phase 1/2 trials in 2026.

  • Financial Details: The collaboration includes significant financial arrangements, with Kelun-Biotech receiving an $80 million upfront payment and potential milestone payments totaling up to $1.25 billion, while Crescent will receive $20 million upfront and up to $30 million in milestones.

  • Private Securities Deal: Crescent Biopharma has also announced a private securities deal expected to raise approximately $185 million, which will fund key clinical data readouts starting in 2027 and extend the company's cash runway into 2028.

  • Market Reaction: Following the announcement, Crescent Biopharma's shares surged over 36% in pre-market trading, reflecting positive investor sentiment regarding the partnership and funding initiatives.

[object Object]
Preview
5.0
11-18Newsfilter
Crescent Biopharma Unveils Inducement Award Grants

  • Equity Inducement Awards: Crescent Biopharma's Board approved the grant of options to purchase 451,448 shares to eight non-executive employees as part of their 2025 Employment Inducement Incentive Award Plan, effective November 14, 2025.

  • Option Details: The options have a 10-year term with an exercise price of $13.02 per share, vesting one-fourth on the first anniversary of employment and monthly thereafter, contingent on continuous service.

  • Company Vision: Crescent Biopharma aims to become a leading oncology company, focusing on innovative cancer therapies, including a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates.

  • Contact Information: For further inquiries, Amy Reilly, Chief Communications Officer, can be reached at amy.reilly@crescentbiopharma.com or 617-465-0586.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Crescent Biopharma Inc (CBIO) stock price today?

The current price of CBIO is 12.99 USD — it has decreased -3.13 % in the last trading day.

arrow icon

What is Crescent Biopharma Inc (CBIO)'s business?

Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

arrow icon

What is the price predicton of CBIO Stock?

Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 25.25 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Crescent Biopharma Inc (CBIO)'s revenue for the last quarter?

Crescent Biopharma Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Crescent Biopharma Inc (CBIO)'s earnings per share (EPS) for the last quarter?

Crescent Biopharma Inc. EPS for the last quarter amounts to -1.49 USD, decreased -90.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Crescent Biopharma Inc (CBIO)'s fundamentals?

The market is revising No Change the revenue expectations for Crescent Biopharma, Inc. (CBIO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -8.78%.
arrow icon

How many employees does Crescent Biopharma Inc (CBIO). have?

Crescent Biopharma Inc (CBIO) has 4 emplpoyees as of December 05 2025.

arrow icon

What is Crescent Biopharma Inc (CBIO) market cap?

Today CBIO has the market capitalization of 180.46M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free